Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis

BMJ Open Gastroenterology

Volumn 4, Issue 1, 2017, Pages

  Bethge, Johannes ^a   Meffert, Silvia ^a   Ellrichmann, Mark ^a   Conrad, Claudio ^a   Nikolaus, Susanna ^a   Schreiber, Stefan ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA4 BETA7 INTEGRIN; ANTIBIOTIC AGENT; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTEGRIN; MESALAZINE; METHOTREXATE; PROBIOTIC AGENT; STEROID; UNCLASSIFIED DRUG; VEDOLIZUMAB;

ADD ON THERAPY; ADULT; ANTIBIOTIC THERAPY; ARTHRALGIA; ARTHRITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CASE REPORT; CLINICAL ARTICLE; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTHESOPATHY; GASTROINTESTINAL ENDOSCOPY; HISTOPATHOLOGY; HUMAN; ILEITIS; LOW BACK PAIN; LYMPHOCYTE; MALE; MIDDLE AGED; MORNING STIFFNESS; PRIORITY JOURNAL; PROCTOCOLECTOMY; PROTEIN EXPRESSION; QUALITY OF LIFE; SPINAL PAIN; SPONDYLARTHRITIS; TREATMENT DURATION; TREATMENT OUTCOME; ULCERATIVE COLITIS;

EID: 85040971018     PISSN: None     EISSN: 20544774     Source Type: Journal    
DOI: 10.1136/bmjgast-2016-000127     Document Type: Article

References (16)

1. Gionchetti P, Calabrese C, Rizzello F. Inflammatory bowel diseases and spondyloarthropathies. J Rheumatol Suppl 2015;93:21-3.
2. Brakenhoff LK, van der Heijde DM, Hommes DW. IBD and arthropathies: A practical approach to its diagnosis and management. Gut 2011;60:1426-35.
3. Jacques P, Van Praet L, Carron P, et al. Pathophysiology and role of the gastrointestinal system in spondyloarthritides. Rheum Dis Clin North Am 2012;38:569-82.
4. Elewaut D, De Keyser F, Van Den Bosch F, et al. Enrichment of T cells carrying beta7 integrins in inflamed synovial tissue from patients with early spondyloarthropathy, compared to rheumatoid arthritis. J Rheumatol 1998;25:1932-7.
5. Singh S, Stroud AM, Holubar SD, et al. Treatment and prevention of pouchitis after ileal pouch-Anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev 2015;(11):CD001176.
6. Herfarth HH, Long MD, Isaacs KL. Use of biologics in pouchitis: A systematic review. J Clin Gastroenterol 2015;49:647-54.
7. Barreiro-de Acosta M, Garcia-Bosch O, Souto R, et al. Efficacy of infliximab rescue therapy in patients with chronic refractory pouchitis: A multicenter study. Inflamm Bowel Dis 2012;18:812-17.
8. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
9. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21.
10. Rubin D, Feagan B, Dryden G, et al. The effect of vedolizumab on extraintestinal manifestations in patients with Crohn's disease in GEMINI 2. Inflamm Bowel Dis 2016;22:105.
11. Baumgart DC, Bokemeyer B, Drabik A, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice-A nationwide consecutive German cohort study. Aliment Pharmacol Ther 2016;43:1090-102.
12. Gisbert JP, Marin AC, McNicholl AG, et al. Systematic review with meta-Analysis: The efficacy of a second anti-TNF in patients wit inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 41:613-23.
13. Van Damme N, Elewaut D, Baeten D, et al. Gut mucosal T cell lines from ankylosing spondylitis patients are enriched with alphaEbeta7 integrin. Clin Exp Rheumatol 2001;19:681-7.
14. Alcazar Navarrete B, Quiles Ruiz-Rico N, Gonzalez Vargas F, et al. [Bronchiectasis following colectomy in a patient with ulcerative colitis and factor V Leiden mutation]. Arch Bronconeumol 2005;41:230-2.
15. Hirten R, Longman RS, Bosworth BP, et al. Vedolizumab and infliximab combination therapy in the treatment of Crohn's disease. Am J Gastroenterol 2015;110:1737-8.
16. Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: A systematic review and network meta-Analysis. Clin Gastroenterol Hepatol 2016;14: 1385-1397.e10.